NRGN and Alzheimer disease: Progress in biomarkers relevant to clinical trials of AD include increased understanding of the role of tau positron emission tomography (PET) in characterizing and staging AD and development of new fluid biomarkers such as neurofilament light and neurogranin that are increasingly integrated into clinical trials [9], [10].